These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation. Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243 [TBL] [Abstract][Full Text] [Related]
5. Bastos AU; de Jesus AC; Cerutti JM Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324 [TBL] [Abstract][Full Text] [Related]
6. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas. Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422 [TBL] [Abstract][Full Text] [Related]
13. Integrating Molecular Testing in the Diagnosis and Management of Children with Thyroid Lesions. Ballester LY; Sarabia SF; Sayeed H; Patel N; Baalwa J; Athanassaki I; Hernandez JA; Fang E; Quintanilla NM; Roy A; López-Terrada DH Pediatr Dev Pathol; 2016; 19(2):94-100. PubMed ID: 26366474 [TBL] [Abstract][Full Text] [Related]
14. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States. Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937 [TBL] [Abstract][Full Text] [Related]
15. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. Lee YA; Lee H; Im SW; Song YS; Oh DY; Kang HJ; Won JK; Jung KC; Kwon D; Chung EJ; Hah JH; Paeng JC; Kim JH; Choi J; Kim OH; Oh JM; Ahn BC; Wirth LJ; Shin CH; Kim JI; Park YJ J Clin Invest; 2021 Sep; 131(18):. PubMed ID: 34237031 [TBL] [Abstract][Full Text] [Related]
16. Mammary analog secretory carcinoma of the thyroid gland: A primary thyroid adenocarcinoma harboring ETV6-NTRK3 fusion. Dogan S; Wang L; Ptashkin RN; Dawson RR; Shah JP; Sherman EJ; Michael Tuttle R; Fagin JA; Klimstra DS; Katabi N; Ghossein RA Mod Pathol; 2016 Sep; 29(9):985-95. PubMed ID: 27282352 [TBL] [Abstract][Full Text] [Related]
17. Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions. Vanden Borre P; Schrock AB; Anderson PM; Morris JC; Heilmann AM; Holmes O; Wang K; Johnson A; Waguespack SG; Ou SI; Khan S; Fung KM; Stephens PJ; Erlich RL; Miller VA; Ross JS; Ali SM Oncologist; 2017 Mar; 22(3):255-263. PubMed ID: 28209747 [TBL] [Abstract][Full Text] [Related]
18. Clinical and Morphologic Features of ETV6-NTRK3 Translocated Papillary Thyroid Carcinoma in an Adult Population Without Radiation Exposure. Seethala RR; Chiosea SI; Liu CZ; Nikiforova M; Nikiforov YE Am J Surg Pathol; 2017 Apr; 41(4):446-457. PubMed ID: 28125451 [TBL] [Abstract][Full Text] [Related]
19. Genetic landscape of papillary thyroid carcinoma in the Chinese population. Liang J; Cai W; Feng D; Teng H; Mao F; Jiang Y; Hu S; Li X; Zhang Y; Liu B; Sun ZS J Pathol; 2018 Feb; 244(2):215-226. PubMed ID: 29144541 [TBL] [Abstract][Full Text] [Related]
20. The Clinicopathological Results of Thyroid Cancer With BRAFV600E Mutation in the Young Population of Fukushima. Iwadate M; Mitsutake N; Matsuse M; Fukushima T; Suzuki S; Matsumoto Y; Ookouchi C; Mizunuma H; Nakamura I; Nakano K; Sakamoto A; Hirokawa M; Ito M; Naganuma H; Hashimoto Y; Shimura H; Yamashita S; Suzuki S J Clin Endocrinol Metab; 2020 Dec; 105(12):. PubMed ID: 32827026 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]